Royalty Purchase Agreements - Palobiofarrma (Details) |
12 Months Ended | ||
|---|---|---|---|
|
Sep. 26, 2019
USD ($)
|
Dec. 31, 2019
USD ($)
|
Dec. 31, 2018
USD ($)
|
|
| Agreements | |||
| Payments to acquire milestones and royalties | $ 19,300,000 | $ 15,000,000 | |
| Proceeds from issuance of long-term debt | 9,500,000 | 7,500,000 | |
| Long-term royalty receivables | 34,375,000 | 15,000,000 | |
| Impairment of long-term royalty receivable | 0 | $ 0 | |
| Royalty Purchase Agreement | Palobiofarma, S.L. | |||
| Agreements | |||
| Number of drug candidates | 6 | ||
| Payments to acquire milestones and royalties | $ 10,000,000 | ||
| Long-term royalty receivables | 10,000,000 | ||
| Impairment of long-term royalty receivable | $ 0 | ||
| Royalty Purchase Agreement | Palobiofarma, S.L. | Silicon Valley Bank Loan Agreement | |||
| Agreements | |||
| Proceeds from issuance of long-term debt | $ 5,000,000 | ||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of drug candidates under the terms of the agreement. No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets. No definition available.
|
| X | ||||||||||
- Definition Long-term royalty receivable non current. No definition available.
|
| X | ||||||||||
- Definition Payments related to purchase of royalty rights. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|